Castle Biosciences, Inc. (CSTL)
| Market Cap | 1.96B |
| Revenue (ttm) | 62.98M |
| Net Income (ttm) | -3.34M |
| Shares Out | 19.94M |
| EPS (ttm) | -0.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $79.17 |
| Previous Close | $80.68 |
| Change ($) | -1.51 |
| Change (%) | -1.87% |
| Day's Open | 79.63 |
| Day's Range | 76.51 - 80.99 |
| Day's Volume | 176,757 |
| 52-Week Range | 23.08 - 81.48 |
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Derma...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Castle--Castle today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2020.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle is scheduled to present a company overview at the 23rd Annual Needham Virtual Growth Conference on Jan. 15, 2021.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #skincancer--Castle today announced it prepaid in full its outstanding term loan facility.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences today announced the closing of its previously announced underwritten public offering.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences announced today the pricing of its underwritten public offering.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle announced today that it has commenced a proposed underwritten public offering.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #cancerdiagnostics--Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx™-Melanoma for Suspicio...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDP2020--Castle today announced the presentation of data on two of its skin cancer gene expression profile tests during the 57th Meeting of ASDP.
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Catalyst Biosciences (CBIO), UFP Industries (UFPI), VeriSign (VRSN), InMode (INMD) and...
Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2020 Results - Earnings Call Transcript
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #earnings--Castle today announced its financial results for the third quarter and nine months ended Sept. 30, 2020.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle's president and CEO will present a company overview at the Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum on Nov. 19, 2020
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #GeneExpressionProfile--Castle Biosciences announced that DecisionDx® DiffDx™-Melanoma is now commercially available.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDP--Castle will deliver two poster presentations at The ASDP 57th Virtual Annual Meeting.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release its financial results for the third quarter ended Sept. 30, 2020, after the close of market on Monday, Nov...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle today announced that it will host an investor webcast to highlight the planned launch of the ConfirmDx®-Melanoma test.
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences Presents Data on DecisionDx-Melanoma at the Virtual European Association of Dermato-Oncology (EADO) Congress.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDS--Castle announced its data were featured in two oral presentations during the 2020 ASDS Virtual Annual Meeting, Oct. 9-11, 2020.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announced that Palmetto GBA MolDx has issued a final expanded local coverage determination for the company's DecisionDx...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDS--Castle announced its data will be featured in oral presentations during the 2020 American Society for Dermatologic Surgery Virtual Annual M...
Castle Biosciences, Inc.'s (CSTL) CEO Derek Maetzold on Q2 2020 Results - Earnings Call Transcript
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 80.95% and 39.02%, respectively, for the quarter ended June 2020.
Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions...
Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q1 2020 Results - Earnings Call Transcript
As of late, it has definitely been a great time to be an investor in Castle Biosciences.
Castle Biosciences (CSTL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Castle Biosciences, Inc. (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Castle Biosciences, Inc. (CSTL) has been struggling lately, but the selling pressure may be coming to an end soon.
Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q4 2019 - Earnings Call Transcript
About CSTL
Castle Biosciences, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary product... [Read more...]
| Industry Diagnostics & Research | IPO Date Jul 25, 2019 |
| CEO Derek J. Maetzold | Employees 133 |
| Stock Exchange NASDAQ | Ticker Symbol CSTL |
Analyst Forecasts
According to 5 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price forecast is 72.80, which is a decrease of -8.05% from the latest price.